
Last updated: 2026-10-29 · Written by: SaiyanMed Research Team · Reviewed against: 16 primary, registry and analytical sources, all linked below · Values marked calculated are our own arithmetic from the formulas, shown so you can reproduce them
Quick answer: Semax is the heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP; C37H51N9O10S; average MW 813.92; monoisotopic 813.3480 Da; CAS 80714-61-0).[1][15] N-Acetyl Semax Amidate is the same seven residues with two covalent end-caps: an acetyl group on the N-terminal amine and an amide in place of the C-terminal acid (Ac-MEHFPGP-NH2; C39H54N10O10S; average MW 854.97; monoisotopic 854.3745 Da; CAS 2920938-90-3).[2][4] The net change is +41.03 Da. It is a different molecule, not a salt form, and not the same thing as N-Acetyl Semax (Ac-MEHFPGP-OH, 855.3585 Da), which is only 0.98 Da heavier and is easy to confuse on a low-resolution mass spectrum.[4] The case for capping rests on Semax’s measured degradation, which proceeds from both ends,[5] and on general peptide-capping studies.[11][12][13] No peer-reviewed study has measured the stability, pharmacology or potency of the doubly capped molecule itself.
Key takeaways
- Four molecules, not two. Semax, N-acetyl Semax, Semax amide and N-acetyl Semax amidate are four distinct structures. A Belgian control laboratory separated three of them by LC-MS at 8.70, 10.89 and 10.26 min.[4]
- Caps are covalent; salts are not. Acetate or TFA counter-ions change the weight of the powder, not the identity of the peptide. “Semax acetate” is Semax plus acetic acid; it carries no acetyl cap.[3]
- Semax is attacked at both ends. With rat brain membranes and glial cells, removal of the N-terminal Met-Glu and the C-terminal Gly-Pro happened at comparable rates.[5] This is why an N-cap alone and a C-cap alone are different propositions.
- Acetylation is not chemically silent. Ac-Semax binds copper(II) differently and lost Semax’s protection against copper toxicity in one cell study.[9] A cap can change behaviour, not only lifetime.
- The 0.98 Da trap. N-acetyl Semax (855.3585) and N-acetyl Semax amidate (854.3745) differ by 0.984 Da (calculated). Use the y1 fragment (116.07 vs 115.09) and retention time to tell them apart.[4]
- Evidence gap. The PubChem record for the doubly capped form was created on 31 December 2024, is fed by vendor deposits and links to no literature or patents.[2] The one peer-reviewed paper that handled the molecule used it as an analytical reference standard.[4]
- Per milligram, the free bases give about 1,229 nmol (Semax) and 1,170 nmol (NA-Semax amidate). As 2 TFA and 1 TFA salts respectively, the figures fall to about 960 and 1,032 nmol (calculated).
At a glance: the four Semax forms
All values below are calculated from the formulas using IUPAC monoisotopic and average atomic masses, then checked against the exact masses and fragment ions reported by Vanhee et al. (Sciensano).
| Property | Semax | N-Acetyl Semax | Semax amide | N-Acetyl Semax Amidate |
|---|---|---|---|---|
| Sequence | H-MEHFPGP-OH | Ac-MEHFPGP-OH | H-MEHFPGP-NH2 | Ac-MEHFPGP-NH2 |
| Formula | C37H51N9O10S | C39H53N9O11S | C37H52N10O9S | C39H54N10O10S |
| Average MW (g/mol) | 813.92 | 855.96 | 812.94 | 854.97 |
| Monoisotopic mass (Da) | 813.3480 | 855.3585 | 812.3639 | 854.3745 |
| Δ vs Semax (mono) | 0 | +42.0106 | −0.9840 | +41.0265 |
| [M+H]+ m/z | 814.3552 | 856.3658 | 813.3712 | 855.3818 |
| [M+2H]2+ m/z | 407.6813 | 428.6865 | 407.1892 | 428.1945 |
| Free N-terminal amine | Yes | No | Yes | No |
| Free C-terminal acid | Yes | Yes | No | No |
| Estimated pI (calculated) | ≈5.4 | ≈3.9 | ≈7.6 | ≈5.4 |
| Net charge at pH 7 (calculated) | ≈−0.8 | ≈−1.8 | ≈+0.2 | ≈−0.8 |
| nmol per mg, free base (calculated) | 1,228.6 | 1,168.3 | 1,230.1 | 1,169.6 |
| LC-MS retention time, Sciensano method | 8.70 min | 10.89 min | not tested | 10.26 min |
| Registry identifiers | CAS 80714-61-0; CID 9811102; UNII I5FAL2585H | none found | none found | CAS 2920938-90-3; CID 172638603 |
Two patterns in Table 1 matter more than any single number. First, the capped forms are more retained on reversed-phase columns than Semax. Removing the charged N-terminal amine makes the molecule more hydrophobic. Second, the two singly capped forms move the pI in opposite directions, while the doubly capped form lands almost exactly where Semax started. That coincidence is why net charge at neutral pH is a poor identity test.
What Semax is, and why its C-terminus is already engineered
Semax was designed in Russia from ACTH(4-10). The ACTH(4-7) fragment Met-Glu-His-Phe is kept, and the native Arg-Trp-Gly end is replaced with the tripeptide Pro-Gly-Pro (PGP).[4][14] The PGP tail was a stability modification in its own right. Proline-rich C-termini resist many carboxypeptidases, and the Myasoedov group reports that the swap increased resistance to peptidases.[14] In other words, “plain” Semax is already an end-modified analogue. N-acetylation and C-amidation are a second layer of capping on a molecule that was already redesigned once.
Semax has registry entries in PubChem and the FDA substance registry.[1][15] Its scientific literature, mostly from Russian institutes, covers receptor binding in rat brain membranes (Kd ≈2.4 nM),[6] degradation,[5][6][7] enzyme inhibition[10] and animal models.[14] For a general profile, see What is Semax. This article focuses on what the terminal modifications change chemically and analytically.
Mechanism: what each modification does

N-terminal acetylation (+C2H2O, +42.0106 Da)
- Chemistry: converts the free α-amine of Met1 (pKa ≈8–9, positively charged at neutral pH) into a neutral acetamide. The molecule loses one positive charge.
- Enzymes it blocks (in principle): aminopeptidases need a free N-terminal amine. In rat serum, the aminopeptidase inhibitor bestatin blocked up to 66% of total Semax-degrading activity, which identifies aminopeptidases as major degraders.[7] Aminopeptidase-N-type enzymes cleave Semax and its N-terminal analogues to HFPGP.[8]
- What it also changes: the free amine is a copper-binding site. Ac-Semax forms a different Cu(II) complex (CuN3O rather than CuN4) that is more easily reduced. Unlike Semax, it did not protect SH-SY5Y cells from copper toxicity.[9] Zinc binding was similar for both peptides.[9]
C-terminal amidation (–OH → –NH2, −0.9840 Da)
- Chemistry: converts the C-terminal carboxylate of Pro7 (pKa ≈3–4, negatively charged at neutral pH) into a neutral carboxamide. The molecule loses one negative charge.
- Enzymes it blocks (in principle): carboxypeptidases and peptidyl-dipeptidases such as angiotensin-converting enzyme (ACE) generally need a free C-terminal carboxylate. In rat serum, the ACE inhibitor lisinopril blocked about 15% of Semax-degrading activity.[7] With brain membranes and glia, cleavage of Gly-Pro and of the terminal Pro was at least as fast as N-terminal Met-Glu removal.[5]
- Direct evidence on amidated Semax: none found. We located no peer-reviewed stability, binding or activity data for Semax-NH2 or Ac-Semax-NH2.
Both caps together
Blocking both ends removes the exopeptidase entry points that the degradation studies identified. This is the textbook rationale, and capping studies on unrelated peptides support it. Acetylation and/or amidation markedly prolonged the plasma survival of MART-1(27-35).[11] Ac/NH2 thymopentin analogues were stable in human serum.[12] Short antimicrobial peptides show similar effects.[13] The size of the effect is peptide-specific, though. None of these studies is about Semax, and endopeptidases, which cut inside the chain (for example at Pro-Gly or Phe-Pro), are not blocked by end-caps. The prediction that Ac-Semax-NH2 lasts longer is reasonable but unmeasured.
Semax degradation data: the evidence capping relies on

The most detailed Semax degradation dataset is Zolotarev et al. 2006.[5] They incubated tritium-labelled Semax (440 nM) with rat basal-forebrain plasma membranes, glial cultures or neuronal cultures and followed every fragment by HPLC. Their main findings:
- Degradation proceeds from both termini at comparable rates. Dipeptidyl peptidases removing Met-Glu (giving HFPGP) and Gly-Pro (giving MEHFP) dominate early.[5]
- With membranes, HFPGP accumulated at about 3–4× the level of MEHFP, and loss of the C-terminal Pro was greater than loss of Met.[5]
- Neurons degraded Semax much more slowly than glia or membranes.[5]
- An earlier paper from the same group reported a membrane half-life above 1 hour and the sequential route Semax → HFPGP → PGP.[6] Semax and HFPGP also inhibit enkephalin-degrading enzymes of human serum.[10]
| Preparation | Intact Semax remaining (nM, from 440 nM) | Time to 50% intact (calculated) | Intact at 24 h |
|---|---|---|---|
| Basal-forebrain plasma membranes | 370 (15 min), 344 (30 min), 277 (1 h), 157 (2 h), 78 (4 h), 13 (24 h) | ≈1.4 h | ≈3% |
| Glial cultures | 375 (30 min), 306 (1 h), 189 (2 h), 103 (3 h), 26 (24 h) | ≈1.7 h | ≈6% |
| Neuronal cultures | 418 (30 min), 397 (1 h), 371 (2 h), 336 (3 h), 116 (24 h) | ≈11 h | ≈26% |
What this means for capping: earlier descriptions, including our own previous draft, often said Semax is degraded “mainly from the N-terminus”, which made amidation look like an afterthought. The membrane and glia data do not support that. C-terminal Gly-Pro and Pro removal is at least as important as N-terminal Met-Glu removal.[5] In serum, aminopeptidases dominate, with ACE contributing.[7] An N-acetyl-only form addresses one of two observed entry points. The doubly capped form addresses both exopeptidase routes, but whether that measurably extends its lifetime in any matrix has not been published.
| Degradation product | Sequence | Monoisotopic mass (Da) | [M+H]+ (calculated) | Can it come from the doubly capped form? |
|---|---|---|---|---|
| Pentapeptide (N-terminal loss) | HFPGP | 553.2649 | 554.2722 | Only if Ac-Met-Glu is cut off as a dipeptide; the product would then be HFPGP-NH2 (554.2722 − 0.9840 = 553.2882 [M+H]+) |
| Hexapeptide | EHFPGP | 681.3002 | 682.3075 | Requires aminopeptidase on a capped N-terminus (blocked) |
| Pentapeptide (C-terminal loss) | MEHFP | 658.2664 | 659.2737 | Requires peptidyl-dipeptidase on an amidated C-terminus (blocked) |
| Hexapeptide | MEHFPG | 715.2879 | 716.2952 | Requires carboxypeptidase (blocked) |
| Tetrapeptide | FPGP | 415.1987 | 416.2060 | Only via endopeptidase cuts |
| Tripeptide | PGP | 268.1303 | 269.1376 | Only via endopeptidase cuts; product would be PGP-NH2 |
| Met-sulfoxide Semax | M(O)EHFPGP | 829.3429 | 830.3502 | Yes. Oxidation is chemical, not enzymatic, and caps do not prevent it |
Salt forms: what “acetate” and “TFA” do and do not mean
Synthetic peptides are purified by reversed-phase HPLC and freeze-dried with whatever counter-ion was in the mobile phase. That is usually trifluoroacetate (TFA) unless an exchange to acetate or chloride is done. The counter-ion pairs with protonated basic groups. Semax has two of them: the N-terminal amine and the His side chain. Acetylation removes the amine, so N-acetyl Semax amidate has only His (pKa ≈6). It can therefore carry at most about one counter-ion per molecule, and often less, depending on how the material was dried. PubChem’s “Semax acetate” record is Semax with one acetic acid (C39H55N9O12S, ≈874.0 g/mol). It is a salt, not an acetylated peptide.[3]
| Form | Formula weight (calculated) | Peptide fraction by mass | nmol peptide per mg powder |
|---|---|---|---|
| Semax free base | 813.92 | 100% | 1,228.6 |
| Semax · 1 acetate | 873.97 | 93.1% | 1,144.2 |
| Semax · 2 acetate | 934.02 | 87.1% | 1,070.6 |
| Semax · 1 TFA | 927.94 | 87.7% | 1,077.7 |
| Semax · 2 TFA | 1,041.97 | 78.1% | 959.7 |
| NA-Semax amidate free base | 854.97 | 100% | 1,169.6 |
| NA-Semax amidate · 1 acetate | 915.02 | 93.4% | 1,092.9 |
| NA-Semax amidate · 1 TFA | 969.00 | 88.2% | 1,032.0 |
A practical consequence: if a TFA-salt Semax standard and an acetate-salt NA-amidate standard are both weighed at 1.00 mg, the molar amounts can differ by roughly 10–15% before any difference in purity or water is counted. Comparisons between forms in the laboratory should be made on a molar, net-peptide basis.
How to verify which form you have
Every form in Table 1 is cheap to synthesise and visually identical as a white lyophilised powder. Identity therefore comes from data, not labels. The checks below are listed from least to most specific. For background on what MS can and cannot prove, see What mass spectrometry can and cannot confirm.
1. Intact mass at adequate resolution
Electrospray of Semax-family peptides gives [M+H]+, [M+2H]2+ and sometimes a weak [M+3H]3+. Sciensano used the 2+ ion as the precursor for all of them.[4] The doubly capped form gives 855.3818 (1+), 428.1945 (2+) and 285.7988 (3+). Semax gives 814.3552, 407.6813 and 272.1233 (calculated). Common sodium adducts [M+Na]+ are 836.3372 (Semax) and 877.3637 (doubly capped).
The trap: N-acetyl Semax is +0.984 Da heavier than the doubly capped form. That is almost exactly the shift caused by deamidation of an amide or by the 13C isotope peak (+1.003 Da). On a nominal-mass instrument, an [M+H]+ at 856 could be N-acetyl Semax, or the M+1 isotope of the doubly capped form (calculated isotope ratios M0:M+1:M+2 = 100:48:18). Report the monoisotopic peak at ≤5 ppm, or confirm by MS/MS.
| Form | M0 | M+1 | M+2 | M+3 |
|---|---|---|---|---|
| Semax | 100 | 45.1 | 16.5 | 4.3 |
| N-Acetyl Semax Amidate | 100 | 47.6 | 17.6 | 4.8 |
Why ppm accuracy matters here: at m/z 855, 5 ppm is ±0.004 Da. That is more than 200 times tighter than the 0.984 Da gap between the two acetylated forms, so a calibrated high-resolution instrument separates them by mass alone, provided the monoisotopic peak is picked rather than the most intense one. On a unit-resolution single quadrupole, it is the chromatography and MS/MS that do the work.
2. Diagnostic MS/MS fragments
| Ion (calculated) | Semax | N-Acetyl Semax | N-Acetyl Semax Amidate | What it proves |
|---|---|---|---|---|
| y1 (Pro, C-terminus) | 116.071 | 116.071 | 115.087 | C-terminus is amide (115) or acid (116) |
| y2 (Gly-Pro) | 173.092 | 173.092 | 172.108 | Confirms the C-terminal state |
| y3 (Pro-Gly-Pro) | 270.145 | 270.145 | 269.161 | PGP tail present |
| b3 (Met-Glu-His) | 398.149 | 440.160 | 440.160 | N-terminus is acetylated (+42.011) |
| b4 (Met-Glu-His-Phe) | 545.218 | 587.228 | 587.228 | Confirms the N-terminal state |
| Immonium His / Met / Phe | 110.072 / 104.053 / 120.081 | same | same | Composition only, not terminal state |
3. Retention time and elution order
On the Sciensano method, Semax eluted at 8.70 min, the doubly capped form at 10.26 min and N-acetyl Semax at 10.89 min.[4] On this method the order was Semax first and the two acetylated forms later, consistent with the loss of the charged N-terminal amine; elution order is method-dependent, however, and should not be assumed to transfer to other columns or gradients (on the same Sciensano method, N-acetyl Selank amidate eluted before unmodified Selank). Absolute times will not transfer. Co-injection with an authentic standard is the decisive retention test.
4. Purity and degradation products
HPLC-UV purity (214–220 nm) says how much of the absorbance is one peak, not which molecule that peak is. In aged material look for Met-sulfoxide (+15.995 Da, usually eluting earlier), the HFPGP and PGP fragments in Table 3, and, in amidated material, a +0.984 Da deamidation product that would co-elute closely and mimic N-acetyl Semax by mass.
Decision guide for an unknown Semax-family sample
- [M+H]+ ≈814.36 → Semax (check for 830.35 Met-oxide).
- [M+H]+ ≈855.38 with y1 115.09 and b3 440.16 → N-acetyl Semax amidate.
- [M+H]+ ≈856.37 with y1 116.07 and b3 440.16 → N-acetyl Semax (not amidated). Or a deamidated amidate; retention time against standards decides.
- [M+H]+ ≈813.37 with y1 115.09 and b3 398.15 → Semax amide (no N-cap).
- Mass matches but the certificate lists only HPLC purity → identity is unconfirmed; request MS/MS or co-injection data.
- Counter-ion or net peptide content not stated → molar amounts are uncertain by up to about 20% (Table 4).
What the evidence can and cannot say
| Claim often made | Evidence available | Status |
|---|---|---|
| Semax is degraded by peptidases in serum and brain tissue | Rat serum inhibitor study; rat membrane and cell-culture kinetics[5][6][7] | Supported (rat, in vitro) |
| Degradation is mainly N-terminal | Zolotarev 2006: both termini at comparable rates[5] | Not supported |
| N-acetylation slows Semax aminopeptidase cleavage | Aminopeptidase role in serum[7]; N-terminal analogue data[8]; no verified Ac-Semax measurement cited here | Plausible, not directly shown |
| N-acetylation leaves Semax chemistry unchanged | Magrì 2016: altered Cu(II) complex, lost cell protection[9] | Contradicted |
| Amidation further increases stability of Semax | No Semax-specific data; general capping studies{c(11,12,13)} | Inferred only |
| NA-Semax amidate has a measured half-life or potency | No peer-reviewed study found; PubChem lists no literature{c(2)} | Unmeasured |
| NA-Semax amidate is X-times stronger than Semax | No comparative study exists | Unsupported marketing |
One frequently cited 2025 mouse study compared Semax with “its derivative”.[14] The full text identifies that derivative as the heptapeptide Met-Glu-Asp-Arg-Pro-Gly-Pro, a sequence analogue with no end-caps. It is not N-acetyl Semax amidate, and the study cannot be used as evidence about the capped form.
Myths vs evidence
| Myth | What the evidence shows |
|---|---|
| “N-Acetyl Semax and N-Acetyl Semax Amidate are the same thing.” | Two molecules, 0.984 Da apart, separated chromatographically.[4] Some registries and shops list one name as a synonym of the other (PubChem’s amidate record carries “N-acetyl semax” as a synonym[2]), which feeds the confusion. |
| “Semax acetate is the acetylated version.” | Acetate is a counter-ion; the peptide is unchanged.[3] Acetylation is a covalent cap that changes the formula. |
| “NASA and Adamax are the same compound.” | Adamax is a separate vendor name for a different, structurally larger Semax analogue. Whatever its exact structure, it is not C39H54N10O10S. |
| “Capping only adds stability.” | Acetylation changed metal coordination and removed a protective effect in cells.[9] Caps can change function. |
| “Semax degrades only from the N-terminus, so amidation is cosmetic.” | C-terminal Gly-Pro/Pro loss was at least as fast as N-terminal loss in rat brain preparations.[5] |
| “The capped form has a proven longer half-life.” | No published measurement. It is a prediction from chemistry and from other peptides. |
| “A 99% HPLC purity confirms it is the amidate.” | Purity is not identity. Only MS/MS (y1 115.09 plus b3 440.16) or co-injection confirms both caps. |
| “The 2025 Alzheimer-model paper studied NA-Semax amidate.” | It studied an uncapped sequence analogue, MEDRPGP.[14] |
Glossary
- Acetylation (N-terminal): covalent addition of CH3CO– to the N-terminal amine; +42.0106 Da.
- Amidation (C-terminal): replacement of the terminal –COOH by –CONH2; −0.9840 Da.
- Aminopeptidase: exopeptidase that removes residues from a free N-terminus.
- Dipeptidyl peptidase / peptidyl-dipeptidase: enzymes removing two residues from the N- or C-terminus respectively; ACE is a peptidyl-dipeptidase.
- Endopeptidase: enzyme cutting within the chain; not blocked by end-caps.
- Counter-ion (salt form): acetate, TFA or chloride paired with protonated basic groups; changes powder weight, not peptide identity.
- Monoisotopic mass: mass using the most abundant isotope of each element; what high-resolution MS reads for the first isotope peak.
- b/y ions: MS/MS fragments containing the N-terminus (b) or C-terminus (y); shifts in them locate a modification.
- Net peptide content: mass fraction of a lyophilised powder that is peptide, after counter-ions and water.
- pI: pH at which the net charge is zero; values here are estimates from standard pKa sets (N-terminus 8.6, C-terminus 3.6, Glu 4.25, His 6.5).
Frequently asked questions
What is the difference between Semax and N-Acetyl Semax Amidate?
Both share the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Semax has a free amine and a free acid at its ends (C37H51N9O10S, 813.92 g/mol). N-Acetyl Semax Amidate has an acetyl cap on the N-terminus and an amide at the C-terminus (C39H54N10O10S, 854.97 g/mol), a net +41.03 Da change. The caps are covalent, so it is a different molecule rather than a salt form.
Is N-Acetyl Semax the same as N-Acetyl Semax Amidate?
No. N-Acetyl Semax (Ac-MEHFPGP-OH, 855.3585 Da) has only the N-terminal cap. The amidate (Ac-MEHFPGP-NH2, 854.3745 Da) has both. They differ by 0.984 Da and elute at different times on LC-MS. MS/MS separates them by the y1 ion: 116.07 for the acid, 115.09 for the amide.
What is the molecular weight of N-Acetyl Semax Amidate?
The formula is C39H54N10O10S. The average molecular weight is 854.97 g/mol and the monoisotopic mass is 854.3745 Da. The expected ions are [M+H]+ 855.38 and [M+2H]2+ 428.19. A salt form weighs more per molecule: about 915 g/mol with one acetate, or 969 g/mol with one TFA.
Is Semax acetate the same as N-Acetyl Semax?
No. Semax acetate is Semax paired with acetic acid as a counter-ion; the peptide itself is unchanged. N-Acetyl Semax carries a covalent acetyl group on its N-terminal amine, which changes the formula to C39H53N9O11S.
Is N-Acetyl Semax Amidate more stable or stronger than Semax?
Its stability, potency and pharmacology have not been measured in any peer-reviewed study. Semax is degraded from both ends in rat brain preparations, and end-capping protects other peptides, so improved stability is a reasonable prediction. It is not a demonstrated property, and no study supports a fold-potency claim.
Why was the Pro-Gly-Pro tail added to Semax?
Semax replaces the Arg-Trp-Gly end of ACTH(4-10) with Pro-Gly-Pro to improve resistance to peptidases. Semax is therefore already end-modified. Acetylation and amidation add a second layer of terminal protection.
How can a lab confirm which Semax form is in a sample?
Measure the intact monoisotopic mass at high resolution, then confirm the terminal state by MS/MS. A b3 ion at 440.16 indicates N-acetylation, and a y1 ion at 115.09 indicates C-amidation. Ideally co-inject an authentic standard. HPLC purity alone cannot establish identity.
Are there published studies on N-Acetyl Semax Amidate?
Very few. The one peer-reviewed paper that handled the exact molecule used it as an analytical reference standard in a forensic LC-MS method. Its PubChem record dates from December 2024 and lists no literature or patents. The published copper-binding data concern N-acetyl Semax, not the amidate.
Where to go next
For the general profile of the parent peptide, read What is Semax. For how sequences, fragments, terminal modifications and salt forms fit together across research peptides, see the peptide identity hub. For the limits of a mass spectrum, see What mass spectrometry can and cannot confirm.
References
- PubChem CID 9811102: Semax (Met-Glu-His-Phe-Pro-Gly-Pro), CAS 80714-61-0
- PubChem CID 172638603: N-acetyl semax amidate (Ac-MEHFPGP-NH2), CAS 2920938-90-3; record created 31 Dec 2024
- PubChem CID 155977617: Semax acetate (1:1 acetic acid component)
- Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: an incentive for controlling agencies to prepare for future encounters of the kind. Drug Test Anal 2020;12:371–381 (Sciensano author copy; PubMed 31667971)
- Zolotarev YuA, Dolotov OV, Inozemtseva LS, et al. Degradation of the ACTH(4-10) analog Semax in the presence of rat basal forebrain cell cultures and plasma membranes. Amino Acids 2006;30:403–408
- Dolotov OV, Zolotarev YuA, Dorokhova EM, et al. The binding of Semax to plasma membranes of the rat forebrain basal nuclei and its biodegradation. Bioorg Khim 2004;30:241–246
- Potaman VN, Alfeeva LY, Kamensky AA, Nezavibatko VN. Degradation of ACTH/MSH(4-10) and its synthetic analog semax by rat serum enzymes: an inhibitor study. Peptides 1993;14:491–495
- Shevchenko KV, V’yunova TV, Nagaev IYu, et al. Proteolysis of Semax analogues with different N-terminal amino acids by aminopeptidases. Bioorg Khim 2011;37:475–482
- Magrì A, Tabbì G, Giuffrida A, et al. Influence of the N-terminus acetylation of Semax on copper(II) and zinc(II) coordination and biological properties. J Inorg Biochem 2016;164:59–69
- Kost NV, Sokolov OYu, Gabaeva MV, et al. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim 2001;27:180–183
- Brinckerhoff LH, Kalashnikov VV, Thompson LW, et al. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-1(27-35) peptide. Int J Cancer 1999;83:326–334
- Heavner GA, Kroon DJ, Audhya T, Goldstein G. Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides 1986;7:1015–1019
- Nguyen LT, Chau JK, Perry NA, et al. Serum stabilities of short tryptophan- and arginine-rich antimicrobial peptide analogs. PLoS One 2010;5:e12684
- Radchenko AI, Kuzubova EV, Apostol AA, et al. The potential of the peptide drug Semax and its derivative for correcting pathological impairments in the animal model of Alzheimer’s disease. Acta Naturae 2025;17:110–120
- FDA Global Substance Registration System, UNII I5FAL2585H: Semax
- MedChemExpress catalogue entry HY-P3588: N-Acetyl semax amidate (supplier listing, used only for the identifier)
Research Use Only Disclaimer
Related research: Adamax vs Semax: What the Evidence Actually Shows (and How to Verify It); What Is Semax; Semax.
This article is for laboratory and analytical education only. The compounds discussed are research chemicals for in-vitro research use only (RUO). They are not drugs, foods, supplements or cosmetics and are not for human or animal use. Nothing here is medical advice, a protocol for administration, or a claim about any effect. Animal, cell and analytical literature is cited for scientific context only.